Objective: to estimate the prevalence of TaqIA, -141C and rs6280 polymorphisms of the ANKK1, DRD2 and DRD3 genes and evaluate their association with the occurrence of metabolic syndrome in patients with refractory schizophrenia. Method: cross-sectional study conducted in the Extended Western Region of Minas Gerais, with refractory schizophrenic patients using the antipsychotic clozapine. Sociodemographic, clinical, anthropometric, biochemical and genetic data were collected. Univariate analysis of the data was performed. Results: seventy-two patients participated in the study and the occurrence of Metabolic Syndrome was observed in 47.2% of them. There was no association between Metabolic Syndrome and the studied polymorphisms. There was a statistically significant difference in the low HDL parameter with homozygous genotype for the C allele of the -141C polymorphism of the DRD2 gene. Conclusion: a high prevalence of MS was evidenced. The -141C polymorphism was associated with low HDL.
Introduction
Schizophrenia is considered one of the most serious mental disorders nowadays, since its progression affects the quality of life of individuals who experience the disease and also of their relatives (1) . Schizophrenia affects more than 21 million people worldwide and is considered a major public health problem (1) (2) . This disease is manifested mainly by the presence of positive symptoms (change in the thinking process, perceptions and affection) and negative symptoms (affective-volitional blunting, cognitive losses and depressive symptoms) (2) .
Approximately 40% of people with schizophrenia do not present adequate response to drug treatment and persist with symptoms of the disease; they are known as refractory schizophrenic people (1) (2) (3) . Although there is no single, globally accepted consensus, refractory schizophrenia can be characterized by partial response, for at least five years, to three different types of antipsychotics (at least two with different chemical structures); intolerance to adverse effects; and relapses or symptomatic deterioration despite the use of appropriate doses of the drugs (3) (4) . The atypical antipsychotic clozapine is considered the gold standard for the drug treatment of refractory schizophrenia, being associated with clinical improvement and decreased hospitalizations (4) (5) .
In this context, studies have indicated that genetic polymorphisms of dopaminergic pathways are related to etiopathogenesis and drug response to treatment, as well as to a greater susceptibility to clinical alterations.
Unique or Single Nucleotide Polymorphisms (SNPs) consist in a variation of the DNA sequence caused by a single nucleotide exchange in the genome sequence.
Some SNPs alter the amino acid composition of the protein and the expression of the receptor, which may have an effect on the phenotype of an individual, and can also serve as molecular markers of predisposition to certain types of diseases. The ability to detect polymorphisms at the DNA level is the basis of several studies that aim to identify whether this variation causes or contributes to a specific phenotype (5) (6) .
Among the genetic polymorphisms of the most studied dopaminergic pathway are the TaqIA, -141C and rs6280. These variants are located in the ANKK1, DRD2 and DRD3 genes, respectively, which have already been addressed by other authors in the literature, relating them to the response to antipsychotics and metabolic alterations of the individuals making use of this drug treatment (4) (5) . However, further in-depth analyses of how these variants in the DNA sequence can influence metabolic alterations in the carriers of these polymorphisms are necessary, as this theme is still little elucidated (7) . The abovementioned polymorphisms occur in genes encoding proteins that contribute to adequate signaling of neurotransmitters in the mesocorticolimbic pathway or ventral tegmental area. These regions play an important role in motivation, guided thinking, affective balance and in the reward system, the latter being responsible for the feeling of satiety and appetite.
Psychotropic drugs act primarily in these regions by lowering dopamine (DA) levels and therefore reducing psychotic symptoms. However, at very low levels, they can lead to cognitive impoverishment, depression and metabolic alterations (8) .
One of the potential consequences of this biochemical process is a condition known as Metabolic Syndrome (MS) (6) (7) (8) (9) . MS is characterized by a set of risk factors that include abdominal obesity, insulin resistance, dyslipidemia and hypertension. The prevalence of MS in patients with refractory schizophrenia compared to patients with other forms of schizophrenia is higher and has more drastic repercussions, reaching 69% (9) . Although the causal relationship between refractory schizophrenia and MS is not fully understood, there is evidence of the association between second-generation antipsychotics and the development of this syndrome.
It has been suggested that the presence of negative symptoms may increase the risk, which may be associated with the sedentary lifestyle and the poor quality of life resulting from this condition (10) (11) .
The genetic analysis of refractory schizophrenic patients can become an essential tool in the perspective of a care plan using genetic counseling, which can serve as a basis to guide the drug treatment and consequently provide a better quality of life for these notably more severe patients. In view of the above, the present study aims to estimate the prevalence of TaqIA, -141C and rs6280 polymorphisms of the ANKK1, DRD2 and DRD3 genes and to evaluate their association with the occurrence of MS in refractory schizophrenic patients.
Method
This is a cross-sectional and analytical study carried (12) . Pregnant women, participants who were not fasting, and those who had www.eerp.usp.br/rlae concentration (>150mg/dL) or use of medication to reduce it; low HDL-c (< 40mg/dL in men or < 50mg/dL in women) or on use of low HDL-c medication (11) . The genetic analysis of peripheral blood samples consisted of five steps: the first one was the extraction of genomic DNA using the QIAamp Mini Blood Kit 
Results
An unintentional finding of the study was that both genders were equally represented among the 72 patients with refractory schizophrenia in use of clozapine (50%).
The average age of the participants was approximately 43 years.
It was verified that the prevalence of MS in the studied population was 47.2%, being more frequent among females (58.8%), but it was also observed that males also had a high incidence rate (41.2%). 
clozapine, in which a prevalence of 65.6% of MS was found in those who had used this medication for more than 5 years. Table 2 shows the association of the studied polymorphisms with MS. Regarding genotypic and allelic analyses, there was no statistically significant difference with MS (p > 0.05).
There was no association considering the three components of MS, high blood pressure, central obesity and hypertriglyceridemia according to the polymorphisms of interest in this study. Low HDL showed a significant association with homozygous genotype for the Ins C allele of the -141C polymorphism of the DRD2 gene (p < 0.05), as described in Table 3 . Pinto JAF, Freitas PHB, Nunes FDD, Granjeiro PA, Santos LL, Machado RM.
As for hyperglycemia, the only polymorphism that presented a statistically significant association was the rs6280 of the DRD3 gene, in which the homozygous genotype for the T allele had a higher prevalence and was associated with non-hyperglycemia, as shown in the table below (Table 4) . The result of the analysis of the factor associated with the -141C variant of the DRD2 and rs6280 genes, component of the syndrome, low HDL, is shown in Table   5 . The homozygous genotype for the Ins C allele of the -141C polymorphism (OR: 19.8) was associated with low HDL, that is, in this study, it was evidenced that a patient diagnosed with refractory schizophrenia who presented the -141C variant of the DRD2 gene and had the homozygous genotype for the Ins C allele was almost 20-fold more likely to present a low HDL level when compared to the heterozygous genotype. 
Discussion
This investigation brings as one result the non-association of the TaqIA, -141C and rs6280
polymorphisms of the dopaminergic system with MS.
However, it is a very relevant investigation because it showed the components that can lead to MS. In addition, a better elucidation of these factors is important to avoid other disastrous complications in the health of these patients (14) .
Metabolic disturbances are more prevalent in schizophrenic patients than in the general population and this may translate into an increased risk of chronic degenerative diseases and even mortality in this group (14) . According to Papanastasiou (2013), women tend to have increased rates of MS compared to men, a datum corroborated in the present study. However, that data must be carefully interpreted; men are likely to be at increased risk of developing cardiovascular disease as the possible result of a combination of unhealthy lifestyles and lack of health care when compared to women (15) (16) .
The present study revealed a statistically (17) (18) .
A study conducted in 2010 found that significant weight gain was confirmed after 6 weeks of treatment with risperidone or olanzapine in the population of patients with the -141C Del allele. (19) . In the present investigation, the Del C allele was also observed to have the highest frequency.
An investigation that sought to characterize the metabolic profile of patients who presented the first episode of schizophrenic outbreak reported a higher prevalence of low HDL in this group than the general population, but there was no association with the genetic profile of this population (20) . Low HDL levels predict increased cardiovascular risk, while high HDL levels are associated with a drop of up to 40% in cardiovascular risk compared to low HDL alone; that is to say, when HDL levels are below the recommended levels, there is risk of complications, especially of cardiac nature (21) (22) .
There are studies that provide evidence of the association of altered glycemic levels with schizophrenia, but no association with the rs6280 polymorphism of the DRD3 gene has been found in the literature (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . A study that analyzed the The monitoring of this metabolic alteration is fundamental for the evaluation of cardiovascular risk.
The imbalance of this marker is an indicator of risk for chronic-degenerative diseases and increased mortality.
Routine follow-up on a regular basis and education on healthy lifestyle are necessary to minimize the risks of complications (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The hypotheses raised in this study suggest that the health care for refractory schizophrenic patients using clozapine must be comprehensive, and the planning of strategies aimed at minimizing the risk of metabolic alterations should be one of the main goals of the individual therapeutic plan for these patients (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
The findings of this study indicated relevant issues when highlighted the vulnerability to which refractory schizophrenic patients are exposed. Metabolic changes increase the risk for the development of cardiovascular diseases and other health implications, which directly interfere with the quality of life of these patients. Therefore, it is essential to develop planned actions and periodic monitoring of plasma levels of biochemical markers that may lead to MS in order to prevent metabolic alterations.
In this sense, it is important that professionals directly involved in the care of these patients know their different metabolic profiles and the possible adverse effects to which they are exposed, so as to conduct the appropriate treatment for each of them.
Awareness of the possibility of these effects must also be raised among patients, allied to promotion of healthy habits, especially regarding a healthy diet and the practice of physical activity.
The limitations of this study are related to its external validity, considering that the sample was not probabilistic and caution is necessary regarding the generalization of the results. The research design allowed estimating the prevalence of the polymorphisms as well as the associated factors, and it is not possible, therefore, to make cause-effect inferences. In addition, we suggest the development of longitudinal researches to improve the understanding of aspects pertinent to the development of MS, establishing associations with the polymorphisms of interest. However, the chosen design provided satisfactory responses to the guiding questions and objectives of the study.
Conclusion
The results of this study indicated that the prevalence of MS in people with refractory schizophrenia using clozapine is high, but there was no association with the polymorphisms of interest. The ancestral genotype appeared to be a protective factor against hyperglycemia in this sample. Therefore, these findings point to the need to carry out further studies involving genetic analyses and MS in patients with refractory schizophrenia in order to guide the drug treatment and promote a better quality of life of this clientele.
